Avita Medical assumed with a Buy at Lake Street

Lake Street assumed coverage of Avita Medical (RCEL) with a Buy rating and a price target of $8, down from $14. Although guidance was cut materially, the company reiterated confidence in a second half recovery and the firm views this as “a prudent reset rather than a structural impairment,” the analyst tells investors.